Patents Examined by Mary Mosher
  • Patent number: 7344830
    Abstract: A change in viral tropism occurs in many HIV positive individuals over time and may be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus may be shifted back to CCR5-mediated entry after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment and clinical management of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CCR5- or CXCR4-specific strains. The diagnostic methods may be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time.
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: March 18, 2008
    Assignee: Health Research Inc.
    Inventors: Sean Philpott, Barbara Weiser, Harold Burger
  • Patent number: 6716431
    Abstract: The nonstructural protein 4 (NSP4) in the SA11 ATCC rotavirus strain has a histidine at amino acid position 47. This substituted form is more cytotoxic than the NSP4 of the Australia rotavirus strain, which has an asparagine at amino acid position 47. The histidine at amino acid position 47 is mutagenized to another amino acid to produce an alternative form of NSP4 which has reduced toxicity, while retaining its antigenicity and immunogenicity. NSP4 having a glutamic acid at amino acid position 48 is more cytotoxic than NSP4 having a lysine at amino acid position 48. The lysine at amino acid position 48 is mutagenized to another amino acid other than glutamic acid to produce an alternative form of NSP4 which has reduced toxicity, while retaining its antigenicity and immunogenicity.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: April 6, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Peng Tian, Timothy J. Zamb, Stephen A. Udem
  • Patent number: 6136320
    Abstract: The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expression of a surface antigen of a viral pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a transgenic plant. This gene is then transferred to plant cells using a procedure that results in its integration into the plant genome, such as through the use of an Agrobacterium tumenfaciens plasmid vector system. Preferably, the foreign gene is expressed in an portion of the plant that is edible by humans or animals. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, preferably in the form of a fruit or vegetable juice which can be taken orally.
    Type: Grant
    Filed: July 7, 1998
    Date of Patent: October 24, 2000
    Assignee: Prodigene, Inc.
    Inventors: Charles Joel Arntzen, Dominic Man-Kit Lam
  • Patent number: 4997755
    Abstract: A microbiological process is described for the preparation of 6-desmethyl-6-.beta.-hydroxymethyl and 6-desmethyl-6-.beta.-carboxylovastatin derivatives and 8-acyl analogs thereof.
    Type: Grant
    Filed: April 14, 1988
    Date of Patent: March 5, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Joanne M. Williamson, David Houck, Edward S. Inamine
  • Patent number: 4977083
    Abstract: Improved processes for preparing A54145 components and cyclic peptide derivatives (A54145 compounds) comprising: (1) feeding alkanoic or alkenoic acids or alcohols, or esters or salts thereof, (2) feeding glucose at a rate from about 6-9 g/L/day, or (3) feeding enzymatic soy digest at a rate from about 2-4 g/L/day to an A54145-producing culture during its fermentation and recovering the A54145 compound, are provided.
    Type: Grant
    Filed: April 11, 1988
    Date of Patent: December 11, 1990
    Assignee: Eli Lilly and Company
    Inventor: LaVerne D. Boeck